INTRODUCTION

Pain Control
Pain, of all our senses, is unique in that the sensory aspects of the stimulus come with unpleasant psychological effects. The former component can be easily assessed in animals whereas measurement of the latter is more problematic. There is still considerable scope for improvement in the treatment of pain despite recent advances in therapeutic agents for pain conditions such as the triptans for migraine and the cyclooxygenase 2 (COX-2) inhibitors. Nevertheless, the main approaches to therapy are still based on old drugs such as aspirin, opium and local anaesthetics. In the case of pain from nerve injury, antidepressants or anticonvulsants are often used, drugs that were never designed as analgesics.
The sensory pathways that underlie pain run from the periphery through the spinal cord and brain stem and project to diverse areas of the brain that monitor and generate the sensory and affective components of the stimulus. Application of a noxious stimulus rapidly induces gene expression within the peripheral nerves and the CNS and different types of pain states recruit distinct physiological and pharmacological profiles. Unlike many other CNS disorders, pain can be targeted from both within the CNS and at the level of the peripheral sensory nerves.
Pain as a Sensory Message
Apart from the potential for the development of new targets and strategies for the treatment of clinical pain syndromes, the study of pain is a model for the investigation of how the nervous system deals with, and adapts to inputs from the outside world. Plasticity is inherent in the sensory pathways in that the neuronal systems alter in different pain states. There is plasticity in the anatomy, physiology and pharmacology of the transduction and processing of pain and of the modulation of pain systems at multiple levels. This ability of the CNS to change function is not simply an intellectual challenge but has direct implications for patients. This is of great importance in the consideration of a rational basis for the treatment of neuropathic and inflammatory pain, the two major types of pain, where tissue and nerve damage can lead to alterations in both peripheral and central pain signalling systems. Pain can be used to shed light on some of the broad issues in neurobiology, using the impact of a noxious stimulus to determine the mechanisms that maintain function in normal conditions and those that underlie plasticity, as well as the processes that lead to the disruption of normal function during chronic disease. The recent rapid progress in pain research is due in large part to advances in genetics and cellular and molecular techniques. Research on the cellular and molecular aspects of peripheral sensory neurone transduction has stimulated the development of novel analgesics and has wider ranging neurobiological implications. The challenge now is to combine these advances with physiological and pharmacological techniques to study the integrated function of the nervous system in the context of sensory events related to the clinical problem of pain.
Problems and Provisos
The aim of this overview is to summarize some of the potential targets at peripheral levels where molecular approaches have suggested targets for novel analgesic therapy. If and when drugs are produced with selective actions at these targets then clinical studies will be of the utmost importance in the determination of effectiveness and the relative balance between wanted and unwanted effects of these novel agents. Thus a major issue in the study of pain using molecular and genetic approaches is that these issues have to be built into the studies of say, knock-out animals. It is no longer sufficient to report a behavioural change to a noxious stimulus in a mouse and then equate that with a role of that system in pain or analgesia. Given that there may be motor, arousal, motivational or other sensory effects of gene deletion, it is quite possible that the phenotypical change seen bears no relation to pain processing. Furthermore, due to different substrates for different types of pain and the plasticity within the processing and modulating systems, it is clear that many targets will only be revealed by appropriate pain models spanning modalties, intensities and time.
A key issue is that the molecular approaches will stand or fail on integrated physiological study of human painful diseases and disorders, in a manner that will permit an understanding and exploitation of advances in genomics. Given the variety of pain states and symptoms seen in clinical medicine, sophisticated integrative neurobiological approaches are needed in order to tease out the roles of particular proteins. The plasticity of both pain transmission and modulation means that models of inflammation and nerve injury will be a prerequisite for a full analysis of the roles of a channel or receptor. In the past, behavioural studies of nociceptive reflexes have often been used as the main outcome measure in the assessment of, for instance, transgenic mice. Although important, this endpoint does not always completely reflect the complexity or subtlety of nociceptive processing, and so multiple mechanistic studies will surely be more useful. In this respect, the intensity of a stimulus is also a key issue. By way of example, the NMDA receptor for glutamate, in common with other neuronal functions, plays a role in persistent intense painful states. Likewise, voltage operated channels will also only be brought into play if the stimulus is appropriate. Thus, a test in which a reflex is used will only address systems that are active during that stimulushere electrophysiological studies under anaesthesia will be critical for the study of systems operating with suprathreshold stimuli that activate supplementary pharmacological targets.
A necessity will be much more refined and selective behavioural studies on nociceptive processing and
The Pharmacogenomics Journal analgesic processing in mutant mice to understand the function of selected molecular targets in a whole organism. Therefore, one important aim is to develop pain models in mice that will allow a better understanding of chronic pain mechanisms in human disease. Such models will also improve testing of novel analgesic drugs. The field of pain research is fortuitous in that many of the behavioural tests used in animals are of obvious significance to the clinical problem of pain. However, many models measure only thresholds and fail to account for the magnitude or duration of effects and as discussed, need to consider non-specific effects.
Compensations within the CNS for gene knock-outs have been rarely discussed. In development many signalling systems have trophic roles and play a part in connectivity, especially as many forms of developmental plasticity are activity-dependent. It is critical that we have a full picture of axonal projections and organization of synaptic connections as well as chemical phenotype of sensory neurones in pain pathways following gene deletion or overexpression of genes in mice. The potential compensations, rearrangements and other changes induced by gene deletion will need to be measured.
Soon there will be novel transgenic technologies such as: (a) tissue-specific knockouts; (b) inducible knockouts; and (c) mutant mice where groups of neurons are selectively labelled. Gene deletion using the cre-lox system will be extremely useful especially when a traditional knock-out is lethal, such as with certain growth factors and NMDA receptors for example. Another method is to transfect neurons with viral vectors encoding cre-recombinase into mice with particular floxed genes.
An emerging and powerful transgenic technique uses bacterial or yeast artificial chromosomes to target large pieces of genomic DNA and allow the expression of marker dyes or functional indicators eg calcium-sensitive proteins. This technology has enormous potential because of its ability to accurately target neurons that express a particular molecule of interest. This technical development is a prime example of the power of combining molecular and integrative techniques. For example, all neurones normally expressing a particular receptor or channel could be tagged for subsequent in vitro or in vivo preparations.
The approach of functional genomics will identify novel molecules that are implicated in nociceptive processing-a problem here is that tissue and nerve damage, the two key causes of pain involve damage-thus molecules that are expressed in conditions of acute or chronic pain may either exclusively or partially play roles in healing and regeneration rather than pain itself. The physiological roles of such molecules will have to be teased out. A clear proviso in the use of human or mouse cDNA chips will be analysis of genes regulated at appropriate times to correlate with integrative physiological endpoints. For example, nNOS is upregulated after nerve injury yet careful analysis reveals that the expression of the enzyme does not coincide with the symptoms.
The techniques need to be refined and here laser capture microdissection (LCM) will allow groups of cells, defined by anatomical area, size or morphology, immunohistochemically or by retrograde tracers or transgenic expression of fluorescent proteins, to be harvested and subjected to gene or protein profiling. There has been only one published study in the field of pain research that combined LCM with cDNA chip analysis to study differential gene expression in two subpopulations of DRG neurons. 1 The immense potential of this technique is largely unexplored.
Finally, little is known about the genetic basis of pain perception in humans although some painful diseases are caused by mutations of single genes. Thus, patients with familial hemiplegic migraine show mutation of a calcium channel subunit 2 and patients with type 1 painful hereditary sensory neuropathy have mutations in serine palmitoyltransferase. 3 Some congenital analgesias are caused by mutations of the gene encoding the high affinity receptor for NGF, trkA. 4 A comparison of monogenetic painful human diseases, as their genetic defects become identified and the detailed analysis of nociceptive mechanisms in appropriate mutant animals, will be an important area.
Another challenging question is the basis of pain sensitivity in the normal population. Analysis of inbred mice strains shows considerable inter-strain variability of nociceptive behaviour, 5 suggesting that much the variability in pain perception in humans resides in genetic variablity. Polymorphisms are known to exist in pain-related candidate genes such as the human -opiate receptor gene. Studies on transgenic mice have also shown that splice variants of the gene could account for much of the variability in the response to morphine. 6 Furthermore, it is clear that some variability to analgesic therapy in humans has a genetic basis.
7
Types of Pain Transmission
In order to study the receptor systems involved in the transmission of pain and its modulation, there is a need for consideration of processes occurring at the peripheral endings of sensory neurones as well as events within the central nervous system. Whereas acute pain, short-lasting and self-limiting, rarely presents as a major clinical problem, persistent pain caused by inflammation or tissue damage can be produced by surgical procedures, trauma, childbirth, cancer and disease states such as arthritis and rheumatism. Inflammatory pain is one of the major pain states. In addition, pain from nerve damage, neuropathic pain, can be produced by trauma, viral infections (post-herpetic neuralgia, AIDS), metabolic disorders (diabetes) and also tumours invading nervous tissue. Inflammation and neuropathy can obviously co-exist in a patientpost-surgical and traumatic pain states and also cancer pains are often mixed in terms of both tissue and nerve damage. In order to develop new strategies for the treatment of pain, models have to be developed that take into account these different mechanisms and the plasticity inherent in the pharmacology. The models have to mimic the clinical aspects of the condition and this approach has been successful, www.nature.com/tpj mainly as a result of interactions between basic scientists and clinicians. The models of inflammation and neuropathy are critical for better analgesics since acute pain does not involve many of the chemical transmitters, receptors and channels important in these more persistent pain states. The animal studies of inflammatory and neuropathic pain allow access to the peripheral endings of C-fibres, the spinal cord itself and drugs can also be given systemically. Overall, the best tactic has been to attempt to show an alteration of a physiological response to a particular painful stimulus by a selective antagonist-if there is a lack of useful tools then genetic approaches can be used to shed light on function.
The roles of particular systems accessed by molecular approaches have been recently reviewed-the aim of this review is to consider some of the issues that arise from these types of studies.
PERIPHERAL EVENTS Inflammation
The transmission of acute pain involves activation of sensory receptors on peripheral C-fibres, the nociceptors, which respond to noxious mechanical and thermal stimulation. However, once tissue damage and inflammation occurs, the production of chemical mediators in the damaged area of tissue becomes of great importance. Thus, prostanoids are produced from local cell membranes, protons are generated and bradykinin is liberated from its precursor in the vasculature and 5HT is also released. The actions of these mediators on their excitatory receptors located on the peripheral C-fibres plays a major role in the sensitization and, at higher concentrations, the activation of C-fibres during inflammation. The former action, sensitization, arises from these mediators acting to reduce the threshold of the sensory nerves so that they now respond to lower intensity stimuli, the basis for the tenderness following injury to tissue.
Neuropathy
Neuropathic pain syndromes are sensory disorders that arise from changes resulting from damage or dysfunction of neuronal pathways, peripheral or central. Not only can there be an ongoing pain in areas of sensory loss but a range of natural stimuli, when applied, may evoke painful or unpleasant sensations. Early animal studies related to neuropathic pain used complete nerve sections. More recent animal models are based on a restricted partial denervation of the hindlimb following sciatic nerve injury. Two of the models involve constriction of the sciatic nerve distal to the spinal cord, either a tight ligation of a portion of the sciatic nerve (partial ligation model), or the loose ligation of the entire nerve (chronic constriction injury (CCI) model). The most recent model uses tight ligation of two of the three spinal nerves which form the sciatic nerve (spinal nerve ligation (SNL) model). The behavioural consequences of these models mimic some aspects of the human symptoms, although the extent and location of the injury differ between the various models.
There is evidence that the aberrations in somatosensory processing which follow partial nerve injury are the culmination of a number of changes in the peripheral nervous system. Studies after nerve section suggest that the generation of ectopic discharges within the neuroma and the dorsal root ganglia (DRG) contributes to these changes. Both peripheral nerves and DRGs contribute to the behavioural responses including allodynia, associated with the SNL model. There are changes in transduction processes and a number of neurochemical changes in the sensory nerves; some peptide transmitters are deleted whilst novel peptides are induced. Neuropathic pain states are therefore generated in the peripheral sensory neurones by events that are independent of peripheral nociceptors. Clustering of sodium channels around areas of nerve damage set up ectopic activity that can spread to the ganglion cells. Sympathetic activity can facilitate these events. Thus membrane stabiliz-ers, drugs that block sodium channels, developed as anticonvulsants, and also agents acting on the sympathetic nervous system have taken their place in the control of neuropathic pain. Can we improve upon these drugs? The answer is that there is considerable potential, based on the finding that Cfibres have unique sodium channels which differ from all other sodium channels in other nerves, neurones and those in the heart. These channels may become important targets for drugs.
Small molecules and ion channels are also important in peripheral hyperalgesia resulting from tissue damage. Molecular approaches have identified many ion channels specific to sensory neurones as important substrates in nociceptor activation and the generation of peripheral hyperalgesia and neuropathy. These issues have been recently reviewed.
8
POTENTIAL NOVEL PERIPHERAL TARGETS Protons Gated Channels
Low pH has long been reported in inflamed tissue and in arthritic joints, skeletal and heart muscle during ischaemia, and in malignant tumours. [9] [10] [11] The build-up of protons can occur as a result of both inadequate perfusion and altered local metabolism. In human volunteers, muscle ischaemia causing a drop in muscle pH to below pH 7.0, is associated with sensations of pain. 10 Infusion of acidic solutions (at pH 5.2) into the skin of human volunteers gives rise to graded sustained pain and hyperalgesia. 12, 13 Here therefore, the simplest of chemical substances can generate pain and hyperalgesia to thermal and mechanical stimuli.
The presence of a sensor sensitive to pH changes in sensory nerves was first reported 20 years ago.
14 Spinal and trigeminal ganglia neurones responded to pH changes with increased membrane permeability to sodium and potassium. This sensor was later noted to be present mainly on small diameter sensory nerve fibres, suggesting a role in nociception. 15 Single unit recordings from sensory nerve endings has established that protons can acti-
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ϩ -gated cation channel. Despite early reports to the contrary, proton-evoked currents in sensory neurones can be carried by Ca 2ϩ . 22 The characteristics of proton-activated currents in sensory nerves are summarised ( Table 1) .
As no channel expressed alone in various expression systems can match exactly or entirely account for native currents, it is more likely that the native currents result from the association of different subunits. For example, ASIC1 and ASIC2 coimmunoprecipitate from rat brain, indicating the existence of heteromultimeric channels.
23
When coexpressed, these two ASICs form channels with novel characteristics; however, as ASIC2 expression is restricted to the brain, this may have little direct relevance to nociception. Several other ASIC genes have been co-expressed and found to form channels with novel characteristics. Of particular interest is ASIC2b, which cannot form functional channels on its own, but combines with ASIC2 and ASIC3 to alter their properties. When coexpressed with ASIC1 however, no novel characteristics are generated. Table 2 shows the characteristics that result from subunit co-expression.
Although expressing combinations of these channels gives rise to currents that share more similarities with currents recorded from sensory nerves, no combination has as yet accounted for all facets of native H ϩ -evoked currents. The ASICs cloned so far are likely to represent no more than potential subunits of functional acid-sensing channels; post-translational modifications and the presence of as-yet unidentified channel genes must be considered.
Conversely, although sensitive to low pH, the channels cloned so far may not function as acid-sensors in their physiological setting. In fact, ASIC2 (BNC) has recently been shown to be necessary for normal touch sensation. 24 BNC Ϫ/Ϫ mice showed normal pH-evoked responses in both wholecell voltage clamp and skin-nerve preparations, yet rapidly adapting (Afibre) mechanosensory fibres could not code normally for the intensity of the stimulus (small membrane displacements). Current injection determined that the abnormal mechanotransduction resulted not from the second step of the mechanotransduction process (turning currents into action potentials) but, therefore, from the first step of the process, turning membrane displacement into currents. Peripheral localisation of both the transcript and BNC1 (ASIC2) protein was seen in lanceolate nerve endings adjacent to the hair follicle, an important site for light touch and brush sensation in hairy skin. 24, 25 A channel necessary for normal mechanotransduction in Drosophila melanogaster has also recently been identified. 26 The cytoskeletal proteins with which these putative mechanosensory channels interact are likely to be important in the mechanism of transduction. Of the proton-sensing ion channels, ASIC1, ASIC2 and ASIC2b have novel PDZ binding domains on their N-terminals, not found on other ASICs, which appear to interact with the PDZ domain-containing protein PICK1 (protein interacting with C kinase). Such proteins may be important in regulating localisation of these channels and in regulating their sensory function, and the novel PDZ interactions of ASIC1 and ASIC2 may suggest a different function for these channels from others in the family.
Previous studies into acid-sensing ion channels have focused on the 27 it became evident that these proton sensors belong to the amiloride-sensitive Na ϩ /degenerin family of ion channels, and share the same structure. Two transmembrane domains bracket a long extracellular loop and both the C and N termini are located intracellularly. Residues in the region preceding the first transmembrane domain are thought to contribute to pore formation and determine the ion selectivity of the channels. 28 Despite the cloning of a large number of ASICs there are fundamental differences between the characteristics of ASICs, either expressed alone or as heteromultimers, and the proton-evoked currents recorded from DRG sensory neurones.
As-yet unidentified channels may, alone or in combination, underlie native proton-evoked nociception.
The Capsaicin Receptor, a Putative Sensor for Convergent Noxious Stimuli
Capsaicin can be painful whether in a culinary or a psychophysical setting. Both the rat and human orthologue of the capsaicin receptor, a heat-activated ion channel, have now been cloned in rats and humans 29, 30 and extensively characterised (see review). 31 Heat, protons, relevant to the issues discussed above, and the endogenous cannabinoid, anandamide may all function as the endogenous ligands for the VR1.
Studies based on capsaicin sensitivity, in situ hybridisation and immunohistochemistry all agree that VR1 is localised in small-diameter sensory (Cfibre) afferents. 29 Discrete immunoreactivity in unmyelinated afferent fibre terminals is seen in the superficial dorsal horn, and in peripheral terminals of sensory nerves, including in the bladder wall. Staining was also seen in nodose ganglia and in medullary structures receiving projections from visceral organs. These co-localisation studies 32, 33 reveal further heterogeneity in primary afferents. Expression of VR1 was found to be higher in TrkApositive neurones (containing substance P and CGRP) than in the other IB4-positive peripheral sensory neurones. However, VR1 is both present and absent in cells in both populations. High levels of VR1 staining (around 10% of VR1-positive cells) have been found in very small diameter and previously little characterised cells that express the receptor tyrosine kinase (Ret) and that do not label for either trkA or IB4. Conversely, it has also been reported that VR1-immunoreactivity co-localized with the P2X3 purinoceptor and IB4, whereas no substantial co-existence with SP-and CGRP-positive terminals was seen.
34
VR1 null mice have now been generated. Their small-diameter DRG neurones lack the normal well-characterised capsaicin-, acid-and noxious heat-gated currents. 35, 36 Behavioural responses to capsaicin injection were eliminated, but normal responses to acute noxious mechanical and thermal
The Pharmacogenomics Journal stimuli were observed. Development of thermal hyperalgesia after peripheral inflammation was severely limited. This indicates that other, not yet identified, heat-gated channels must exist to code acute thermal stimuli but that the VR1 is necessary for development of normal inflammatory thermal hyperalgesia. The VR1 receptor integrates many noxious inputs. VR1 expression confers sensitivity not only to mildly noxious heat (threshold 43-44°C), but also to low pH (pH 5.5) in expression systems. 29 Low pH can also enhance the response of the channel to heat and capsaicin. 29, 32 Small changes in pH (eg to 6.4) enhance VR1 responses to capsaicin and to heat, to such an extent that under even moderately acidic conditions, the temperature threshold for VR1 activation is reduced so much that the channel may be activated at ambient temperatures. 32 This modulation appears to occur via a key extracellular site. 37 It has been suggested that the VR1 is the acid-sensing ion channel on nociceptor terminals. Currents evoked by capsaicin, heat and low pH do share many biophysical properties, but there are apparent discrepancies. Protonactivated channels in sensory neurones are less permeable to Ca 2ϩ than capsaicin-activated channels 22 and show much slower (or no) inactivation. 21, 29 However, these properties may be altered by the presence of protons.
Sensory Neurone-Specific, TTXResistant Sodium Channels
Voltage-gated sodium channels are ubiquitous and are essential for all excitable tissues. Peripheral sensory neurones express multiple distinct sodium channels encoded by different genes. Sodium channel expression in DRG neurones is subject to plasticity and changes are seen not only during development, but also in various pain states. Two types of sodium currents have so far been identified in the DRG, the tetrodotoxin (TTX)-resistant (NaN, SNS) and TTX-sensitive (types I, IIA, III, PN1, NaCh6) currents, which differ in their kinetics and sensitivity to TTX.
Most sodium channels are blocked by tetrodotoxin (TTX). TTX-resistant (TTX-R) currents can be recorded from DRG cells 38, 39 and the algogen, bradykinin stimulates release of CGRP in a TTX-insensitive manner. 40 At least three TTX-R sodium channels expressed in sensory neurones have been cloned and characterised. [41] [42] [43] [44] The sodium channels underlying the TTX-R currents in nociceptors may be an important site for the integration of sensitising stimuli. PGE 2 modulates TTX-R sodium currents in primary afferent neurones 45 and antisense neutralisation of SNS reversibly blocks PGE 2 -induced inflammatory hyperalgesia. 46 PKA and PKC appear to interact to mediate modulation of TTX-R currents in nociceptors. 47 Null mutant mice with targeted disruption of the SNS (PN3) channel were expected to reveal much about the role of these channels in nociception. Null mice DRG neurones give rise to only TTXsensitive sodium currents, and animals display reduced sensitivity to noxious mechanical stimuli. 48 Surprisingly, only mild effects were seen on thermoreception and inflammatory hyperalgesia.
Lowered thresholds for C-fibre activation of dorsal horn neurones and increased TTX-sensitive current density were observed, indicating the existence of developmental and other compensatory mechanisms which may have masked the true function of the channel. This therefore illustrates one of the major factors that can bedevil genetic approaches to pain.
Changes in the expression and function of these sodium channels may make an important contribution to the establishment of certain chronic pain states. Major changes in the subcellular distribution of the TTX-R SNS protein have been reported after CCI, SNL or complete transection of the sciatic nerve. Studies have shown that the transcripts for NaN and SNS are significantly reduced in small diameter DRG neurones. 42, 49 The loss of SNS immunolabelling from the L4-L6 DRG after CCI appears to be correlated with the redistribution and accumulation of the channel protein within the peripheral nerve, proximal to the site of injury. 50 If this has functional implications then simply knocking out the channel may not tell the whole story. In the SNL model of neuropathy, the expression of the SNS protein appears to decrease in the injured DRG (L5/6), whilst protein levels are significantly increased in intact large diameter adjacent L4 DRG neurones. 51 Thus the alteration in channel distribution after peripheral nerve injury exhibits a complex pattern. Similarly, in patients with chronic neurogenic pain, an acute reduction of SNS and NaN-like immunoreactivity has been reported in the cervical DRG. 51 In peripheral nerve fibres just proximal to the site of injury, however, there was an accumulation of both sodium channels, indicating a translocation of pre-synthesized intracellularly-located channel protein to peripheral nerves.
Based on these findings, the SNS sodium channel has been implicated in the pathophysiology of nerveinjured states. 51 At present, there are no selective antagonists of the SNS channel and so its role is difficult to study. However, using antisense to downregulate the functional expression of the channel, it can be shown that interference of its expression or function markedly attenuates the allodynia produced by selective ligation of L5/6 spinal nerves in rats. 50 This is the first evidence that shows an involvement of this channel in some of the symptoms of neuropathic pain. In addition to the changes in constitutive channels, nerve injury induces a switch in the type of sodium channel produced by DRG cells demonstrated by the emergence of a previously silent type III sodium channel gene. 42, 52 The type III sodium channel mRNA is usually only expressed in embryonic neurones and is subsequently downregulated with development. 53 This channel is thought to underlie the TTX-S rapidly repriming Na ϩ current in DRG neurones following peripheral nerve injury 52 and displays a four-fold acceleration of recovery from inactivation, due to a reduced refractory period. 54 Activation of these previously quiescent channels may therefore induce abnormal repetitive firing in injured neurones and may potentially act as ectopic impulse generators. A previous study demonwww.nature.com/tpj strated that TTX-S channels are necessary for the manifestation of ectopic neuronal activity in neuromas and DRG. 55 These findings therefore also support a role for TTX-S sodium channels in the development of neuropathic pain, reflected by the inhibitory effect of TTX on neuronal excitability in neuromas. 56 Thus, the upregulation of TTX-S channels, together with the loss of TTX-R current in the DRG following nerve injury, implies that there is an increase in the relative amount of TTX-S current available for activation.
What is the relative importance of these channels? The answer is not an easy one and only a combination of very careful studies in knock-out animals, preferably inducible ones in order to avoid compensations in development will reveal this. In a sense, the potential produced by the molecular approaches will only be fulfilled when pharmacological agents with selectivity are produced.
P2X3, an ATP-gated Ion Channel
ATP is released from damaged tissue and causes sensations of pain in human volunteers thereby suggesting an important role in pain. 57 However, seven ATP-gated cation-selective ion channels have been cloned and characterised, along with a number of G-protein coupled receptors. Of these, the P2X3 is selectively expressed by nociceptors. Two groups have recently generated P2X3 knock-out mice. Both found that the P2X3 channel was not involved in responses to acute thermal or mechanical stimuli, although dorsal horn neuronal responses to sub-noxious 'warm?' stimuli were reduced, inflammatory pain processing was altered and bladder hyporeflexia were observed. 58, 59 These results indicate that that this channel plays a partial role and possibly more in the pre-pain processing of cutaneous and visceral events.
CENTRAL EVENTS
The arrival of sensory information from nociceptors in the dorsal horn of the spinal cord adds considerable complexity to the study of pain and analgesia since the density of neurones in these areas is equal to or exceeds that seen elsewhere in the CNS.
Interactions between peptides and excitatory amino-acids (EAA) are critical for pain transmission from peripheral nerve to the spinal cord and then to the brain. The AMPA receptor for the EAA sets the baseline response of the spinal neurones and is active during both noxious and innocuous responses. Kainate receptors on terminals and neurones may also be important in the generation of neuronal activity. Release of peptides such as substance P and their receptor actions allows the NMDA receptor for glutamate to be activated. Activation of the NMDA receptor underlies windup, whereby the baseline response is amplified and prolonged even though the peripheral input remains the same. This increased responsivity of dorsal horn neurones is probably the basis for central hypersensitivy. The NMDA receptor is involved in persistent inflammatory and neuropathic pains where it is critical for both the induction and subsequent maintenance of the enhanced pain state. Antagonists at multiple sites on the NMDA receptor complex, including the licensed drug, ketamine, are effective in a number of animal models but also in humans. Both volunteer and clinical studies support the ideas that have come from basic research in that the NMDA receptor appears to underlie the central transmission of inflammatory, postoperative and neuropathic pains. Novel NMDA receptor antagonists are eagerly awaited as the present drugs all have problematic side-effects (see review). 60 Calcium channels on terminals and neurones are important for both transmitter release and neuronal excitability. L, N and P-type calcium channel antagonists have distinct differential and time-dependent effects on acute, neuropathic and inflammatory nociception but are presently generally restricted to spinal routes of administration. 61 Conditional knock-outs will be required since here at central levels the impact of molecular approaches is fraught with problems in that many of the targets are ubiquitous. In this respect, it is interesting to note that mice lacking the calcium channel subunit that comprises the N-type channel have responses in the formalin model of nociception that are almost identical to those seen after administration of the selective blocker, w-conotoxin MV11A, where the more persistent phase appears to require the channel to operate.
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THE FUTURE
So clearly there is plenty of scope for advances in pain research. The recent rapid progress in pain research has been driven by molecular and cell biology. These techniques continue to identify genes potentially important in pain processing, and have stimulated the search for novel analgesic drugs as well as promoting understanding of a number of general neurobiological phenomena, such as activity-dependent plasticity. Yet the function of these genes often remains poorly understood, even though there is now a wide range of transgenic mice that allow examination of particular gene function in the whole animals. The challenge for the future is to combine cellular and molecular advances with physiological and pharmacological techniques to understand the integrated functioning of the nervous system related to the clinical problem of pain.
